AORT vs. NARI, PRCT, NVST, IRTC, NVCR, LIVN, WRBY, ENOV, TNDM, and TMDX
Should you be buying Artivion stock or one of its competitors? The main competitors of Artivion include Inari Medical (NARI), PROCEPT BioRobotics (PRCT), Envista (NVST), iRhythm Technologies (IRTC), NovoCure (NVCR), LivaNova (LIVN), Warby Parker (WRBY), Enovis (ENOV), Tandem Diabetes Care (TNDM), and TransMedics Group (TMDX). These companies are all part of the "medical equipment" industry.
Artivion vs.
Artivion (NYSE:AORT) and Inari Medical (NASDAQ:NARI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, community ranking, profitability, valuation and dividends.
In the previous week, Inari Medical had 1 more articles in the media than Artivion. MarketBeat recorded 3 mentions for Inari Medical and 2 mentions for Artivion. Artivion's average media sentiment score of 0.21 beat Inari Medical's score of 0.06 indicating that Artivion is being referred to more favorably in the media.
Artivion has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. Comparatively, Inari Medical has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.
86.4% of Artivion shares are owned by institutional investors. Comparatively, 91.0% of Inari Medical shares are owned by institutional investors. 8.1% of Artivion shares are owned by insiders. Comparatively, 10.6% of Inari Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Artivion presently has a consensus target price of $31.80, suggesting a potential upside of 3.38%. Inari Medical has a consensus target price of $68.00, suggesting a potential downside of 14.52%. Given Artivion's stronger consensus rating and higher possible upside, equities research analysts clearly believe Artivion is more favorable than Inari Medical.
Inari Medical has higher revenue and earnings than Artivion. Artivion is trading at a lower price-to-earnings ratio than Inari Medical, indicating that it is currently the more affordable of the two stocks.
Inari Medical received 42 more outperform votes than Artivion when rated by MarketBeat users. However, 80.00% of users gave Artivion an outperform vote while only 57.89% of users gave Inari Medical an outperform vote.
Artivion has a net margin of -0.22% compared to Inari Medical's net margin of -13.68%. Artivion's return on equity of 5.15% beat Inari Medical's return on equity.
Summary
Artivion beats Inari Medical on 10 of the 18 factors compared between the two stocks.
Get Artivion News Delivered to You Automatically
Sign up to receive the latest news and ratings for AORT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Artivion Competitors List
Related Companies and Tools
This page (NYSE:AORT) was last updated on 1/21/2025 by MarketBeat.com Staff
Free AORT Stock Alerts